Physician profile
Wilson Ko
NPI 1770560096
$25,103.69
in general payments reported to CMS, 2019-2025
32 companies · $9,669 in 2025
The $9,669 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $734 · 2021: $673 · 2022: $810 · 2023: $1,635 · 2024: $10K · 2025: $9,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Food and Beverage: $6,076 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,340 · Education: $60.50 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,905.00 |
| Food and Beverage | $6,076.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,340.00 |
| Education | $60.50 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $9,051.07 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $8,447.05 | 2019-2025 | Cequa |
| Alcon Vision LLC | $1,999.44 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Dompe US, INC. | $1,170.64 | 2019-2025 | Oxervate |
| Glaukos Corporation | $1,013.15 | 2019-2025 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $603.95 | 2019-2025 | Tecnis Iol, Catalys System, Veritas Vision System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $349.81 | 2019-2021 | |
| Oyster Point Pharma, INC. | $324.95 | 2023-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $320.13 | 2024-2025 | Xdemvy |
| Amgen INC. | $182.39 | 2024-2025 | Tepezza |
| Allergan, INC. | $178.93 | 2019-2022 | |
| Harrow Eye, LLC | $159.63 | 2023-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $157.20 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $144.81 | 2020-2023 | Flarex |
| Novartis Pharmaceuticals Corporation | $133.15 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $121.64 | 2022-2025 | |
| Shire North American Group INC | $106.19 | 2019 | |
| Rxsight INC | $88.43 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| New World Medical,INC. | $86.78 | 2024-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Sight Sciences, INC. | $79.33 | 2022 | |
| Thea Pharma INC. | $68.39 | 2023-2025 | Iyuzeh |
| Coopervision INC. | $65.43 | 2024 | Paragon Crt, Onefit Contact Lens |
| Covidien LP | $49.49 | 2019 | |
| Kala Pharmaceuticals, INC. | $39.24 | 2019 | |
| Akorn Operating Company LLC | $38.72 | 2021 | |
| Astellas Pharma US INC | $22.22 | 2024 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $19.14 | 2024 | |
| Halozyme INC | $19.09 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Ocular Therapeutix, INC. | $13.92 | 2025 | Dextenza |
| Horizon Therapeutics Plc | $12.74 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.